Newsletter
Prescription-cost news, without the noise.
Every two weeks: new drug approvals worth knowing about, grant programs opening or closing, and policy changes affecting Medicare Part D, Medicaid, and commercial formularies. Written by the same editorial team who verifies every drug page.
Subscribe
Enter your email. We’ll send a one-click confirmation link. Double opt-in is required before any newsletter lands.
By subscribing you agree we can send you the RxCopays newsletter. We don’t sell or share your email, ever. Unsubscribe any time (one click, no login). Full privacy policy.
What you’ll get
- New drug approvals with verified copay / PAP links on day one (no waiting to hear about them).
- Grant programs opening or closing — especially for diseases you’ve expressed interest in.
- Medicare Part D / Medicaid / commercial-formulary policy updates that affect real patients.
- Occasional deep-dive guides on PA appeals, cost transparency, and access strategies.
What you won’t get
- Ads or sponsored drug promotions — our editorial promise excludes them.
- More than one email per two weeks (unless an urgent deadline — rare).
- Your email rented, sold, or given to any partner. Period.
See our accuracy policy and partnership rules for how we stay editorially independent.